Scientists can now measure activity of key cancer cell-survival protein, an important step toward inhibiting it

February 6, 2018, American Society for Biochemistry and Molecular Biology
Credit: CC0 Public Domain

A recent study from the University of Michigan Life Sciences Institute and the University of California, San Francisco, has opened new options to further develop a potential cancer-fighting therapy, clearing an early hurdle in the lengthy drug-discovery process.

The findings, published in the Journal of Biological Chemistry, reveal new ways to measure the activity of a that is associated with poor prognosis in cancer patients—heat shock protein 70, or Hsp70—and remove a barrier to developing potential Hsp70-based therapies.

When Hsp70 is present in increased levels, cancer are more likely to survive and become resistant to chemotherapeutics. Conversely, when this protein is inhibited in cells, tumor cells are less able to divide, and they eventually die.

Because of its apparent role in cancer cell survival, researchers are interested in developing drugs that block the protein's activity. But these efforts have been hindered by a lack of Hsp70 biomarkers—measureable surrogates that scientists can evaluate to ensure the compounds they are testing really do what they are supposed to do.

Scientists have found some that affect Hsp70 in an artificial environment, where they can directly measure Hsp70 activity. To move to the next steps in drug development, researchers need to know how the protein is responding in its natural environment.

"And it's a lot more difficult to measure Hsp70 inhibition in a cell," says lead study author Laura Cesa, Ph.D, a former U-M Program in Chemical Biology graduate student, now at the University of Copenhagen Biotech Research & Innovation Centre.

For this study, the researchers set out to determine whether Hsp70 has its own specific client proteins—other proteins that can serve as biomarkers for Hsp70.

"This was an interesting question from a basic research standpoint, but it also has exciting therapeutic indications," Cesa explains. "If we can show that inhibiting Hsp70 results in the degradation of its specific client proteins, then those could be used as biomarkers for future development of Hsp70 drugs for cancer therapy."

The team succeeded in identifying client proteins whose levels can be measured and are directly tied to the activity of Hsp70, meaning they can serve as a proxy for measuring Hsp70.

These biomarkers will now enable scientists to take the small molecules that inhibit Hsp70 in artificial environments and begin testing ways to develop them into actual therapeutics.

The significance of these findings led the study to be chosen as the JBC Editors' Pick for the February 16 issue. This honor is reserved for the top 2 percent of the more than 6,600 papers published in the journal each year, in terms of the overall importance of the research.

Explore further: Discovery of new protein shape could impact cancer and neurodegenerative disease therapies

More information: Laura C Cesa et al, X-Linked Inhibitor of Apoptosis Protein (XIAP) is a Client of Heat Shock Protein 70 (Hsp70) and a Biomarker of its Inhibition, Journal of Biological Chemistry (2017). DOI: 10.1074/jbc.RA117.000634

Related Stories

Discovery of new protein shape could impact cancer and neurodegenerative disease therapies

December 13, 2017
A Virginia Commonwealth University researcher has discovered a new conformation of a common protein group with links to cancer metastasis and neurodegenerative diseases.

Discovery that specific protein modification important in cancer development

February 1, 2013
All proteins are made from chains of amino acids and their functions can be modified by adding small molecules to specific amino acids. One such modification is the addition of a methyl group, which is made of one carbon ...

Universal clamping protein stabilizes folded proteins: New insight into how the chaperone protein Hsp70 works

October 26, 2016
On October 26th Nature will publish a study that overturns the decades-old textbook model of action for a protein that is central for many processes in living cells. Researchers at the FOM Institute AMOLF and the University ...

Researchers characterize Ssb chaperone protein for the first time

December 5, 2016
For 20 years, researchers have tried to find out why the chaperone Ssb is the only member of the widespread Hsp70-chaperone family that is able to bind directly to the ribosome. This question has now been answered at the ...

Inhibitor of Heat Shock Protein is a Potential Anticancer Drug, Study Finds

October 29, 2009
( -- Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging ...

Molecular chaperones help with folding

May 12, 2015
Chaperones are molecular helpers that assist other proteins with folding. One such chaperone is the so-called heat shock protein 60 (Hsp60). This protein forms structures in mitochondria that resemble barrels in which folding ...

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.